Last update 01 Nov 2024

Hangzhou Qihanjiyin Biotechnology Co., Ltd.

Private Company|
2021|
Zhejiang Sheng, China

Overview

Tags

Hemic and Lymphatic Diseases
Neoplasms
CAR-NK

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Hemic and Lymphatic Diseases1
Neoplasms1
Top 5 Drug TypeCount
CAR-NK1
Top 5 TargetCount
CD33 x CLL-11

Related

1
Drugs associated with Hangzhou Qihanjiyin Biotechnology Co., Ltd.
CD33/CLL1 dual CAR-NK cells(Hangzhou Qihan Biotech)
Target
CD33 x CLL-1
Mechanism
CD33 modulators [+3]
Active Org.
Hangzhou Qihanjiyin Biotechnology Co., Ltd. [+1]
Originator Org.
Hangzhou Qihan Biotech Co., Ltd.Hangzhou Qihan Biotech Co., Ltd.Startup
Active Indication
Acute Myeloid Leukemia
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
1
Clinical Trials associated with Hangzhou Qihanjiyin Biotechnology Co., Ltd.
NCT06367673 / RecruitingPhase 1IIT
Clinical Study to Evaluate the Safety and Efficacy of iPSC -NK Cells Targeting CLL1 or CD33 in Patients With Relapsed/Refractory AML
100 Clinical Results associated with Hangzhou Qihanjiyin Biotechnology Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Hangzhou Qihanjiyin Biotechnology Co., Ltd.
Login to view more data
100 Deals associated with Hangzhou Qihanjiyin Biotechnology Co., Ltd.
Login to view more data
100 Translational Medicine associated with Hangzhou Qihanjiyin Biotechnology Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 1 Clinical
1
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
CD33/CLL1 dual CAR-NK cells(Hangzhou Qihan Biotech)
 ( CD33 x CLL-1 )		Acute Myeloid Leukemia
More
Phase 1
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free